Table 2:
Demographics of Patients in SCLC Cohort in Study B-005
| Demographic, n (%) | All SCLC (N=105) | Sensitive CTFI ≥ 90 days (N=60) | Resistant CTFI < 90 days (N=45) |
|---|---|---|---|
| Sex | |||
| Female | 42 (40%) | 25 (42%) | 17 (38%) |
| Male | 63 (60%) | 35 (58%) | 28 (62%) |
| Age | |||
| Median (min, max) | 60 (40, 83) | 59 (44, 79) | 66 (40, 83) |
| < 65 yo | 68 (65%) | 46 (77%) | 22 (49%) |
| ≥ 65 yo | 37 (35%) | 14 (23%) | 23 (51%) |
| ≥ 75 yo | 9 (9%) | 5 (8%) | 4 (9%) |
| Race | |||
| White | 79 (75%) | 47 (78%) | 32 (71%) |
| Asian | 1 (1%) | 1 (2%) | 0 (0%) |
| Black or African American | 1 (1%) | 0 (0%) | 1 (2%) |
| Othera | 24 (23%) | 12 (20%) | 12 (27%) |
| Region | |||
| Europe | 94 (90%) | 56 (93%) | 38 (84%) |
| USA | 11 (10%) | 4 (7%) | 7 (16%) |
| Baseline ECOG | |||
| 0 | 38 (36%) | 27 (45%) | 11 (24%) |
| 1 | 59 (56%) | 30 (50%) | 29 (64%) |
| 2 | 8 (8%) | 3 (5%) | 5 (11%) |
| Smoking status | |||
| Current/former | 97 (92%) | 54 (90%) | 43 (96%) |
| Never | 8 (8%) | 6 (10%) | 2 (4%) |
a
Data on race and/or ethnicity were not collected in France and Belgium because of local regulations.
Abbreviations: SCLC: small cell lung cancer; CTFI: chemotherapy-free interval
Source: Drug Approval Package: ZEPZELCA (lurbinectedin) (Ref. 10)